Introduction
According to the World Health Organization, one in every 100 children is affected by autism spectrum disorder (ASD)1. The core symptoms of ASD are characterized by abnormal social functioning and repetitive and restricted patterns of behavior. However, clinical data have shown that boys have more externalizing disorders such as hyperactivity, aggression, and impulsivity2–5. In contrast, girls with ASD present associated problems such as depression, anxiety, sleeping, or other emotional symptoms2,4. In addition to this heterogeneity, genetic factors play a central role in ASD etiology. Mutations in the Nf1 gene, which cause Neurofibromatosis Type 1 (NF1), have been associated with a higher prevalence of ASD traits, including social and cognitive difficulties6–8. The Nf1+/– mouse, although not a canonical ASD model, reproduces several of these phenotypes9,10 and shows underlying altered neurotransmission11 that parallels mechanisms implicated in ASD pathophysiology. For this reason, the Nf1+/– model provides a valuable tool to investigate ASD-related neurodevelopmental alterations.
Gastrointestinal (GI) disorders co-occur in 83–91% of children with ASD and are increasingly recognized as factors influencing symptom severity12–14. Dysbiosis and impaired intestinal barrier functions have been documented in multiple preclinical models with autism-associated gene mutations, which are correlated with abnormalities in stereotypic behaviors, communication, sensorimotor function, and anxiety15,16. Importantly, interventions such as probiotic treatments have been shown to restore GI function and alleviate some behavioral impairments associated with ASD17,18. These findings underscore the critical role of the gut microbiome in modulating neural circuits and behavior.
The gut microbiota facilitates complex bidirectional communication between the gut and the brain, which is mediated in part by neuropeptides and neurotransmitters19,20. Several neuropeptides, such as neuropeptide Y (NPY), are secreted from enteroendocrine cells in the gastrointestinal tract, allowing this biological process21. NPY, along with peptide YY (PYY), belongs to a family of endocrine peptides that act primarily through G protein-coupled receptors (Y1, Y2, Y4, and Y5) with region-specific effects22. Although NPY is expressed in the gut-brain axis, PYY is almost exclusively expressed by endocrine cells of the digestive system. Preclinical and clinical studies suggest that NPY exerts anxiolytic effects, particularly via Y2 receptor signaling23–28. While NPY is produced in both the central nervous system (CNS) and the enteric nervous system (ENS), its role in maintaining gut microbiota homeostasis remains underexplored.
Given the widespread expression of NPY and its receptors in the gut-brain axis, investigations of its role in this context and its potential implications for ASD pathogenesis are crucial. Furthermore, the role of NPY in ASD pathogenesis remains fully unexplored. Here, we hypothesize that alterations in the brain and gut NPY system expression are associated with gut dysbiosis in ASD. This study aims to elucidate the interplay between neuropeptides and the gut microbiome, advancing our understanding of their roles in ASD.
Methods
Animals
Female and male Nf1+/- mice were obtained from mutant animals C57BL/6N mice backcrossed with 129T2/SvEmsJ. As a control, we used no-transgenic littermates.
Tails were cut at postnatal day (PND) 4–5, and genotypes were determined via PCR reaction (primers used were: NF1 P132-TTCAATACCTGCCCAAGG; P133-ATTGCCAATGACAA; P134-GGTATTGAATTGAAGCAC). A total of fifteen-seven animals were used in this study, distributed across the experimental groups as detailed in the figure legends. The animals remained undisturbed with progenitors until PND21. Offspring animals were housed (2–4 per cage) at PND21 on a 12 h light/dark cycle in ICNAS/University of Coimbra animal facilities. The animals were euthanized by cervical dislocation at PND 60. The hippocampus, amygdala, prefrontal cortex (PFC), intestine, and stool were collected in RNAlater® Solution (Invitrogen) for molecular and biochemical analysis. The samples were stored at −80ºC until further processing. The experiments were carried out following the European Union Council Directive (2010/63/EU), the National Regulations (8/2003), and the Internal Review Board of the University of Coimbra. All results are reported in consistency with ARRIVE (animal research: reporting in vivo experiments) guidelines.
Brain and intestinal DNA extraction
After the animals were euthanized, the hippocampus, PFC and amygdala were isolated, and RNA was extracted with RNeasy Lipid Tissue Kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. The purification included a DNase treatment using the RNase-free DNase Set (Qiagen, Hilden, Germany). Intestinal RNA was extracted using NZY Total RNA isolation kit (NZYtech, Portugal) and was followed by a DNAse digestion step to remove any contaminating genomic DNA.
RNA quality assessment and cDNA synthesis
The DNA and RNA yields and purity of the extracts were measured photometrically using Nanodrop ND-1000 spectrophotometer (LabTech UK). To determine DNA and RNA purity, the A260 nm/A280 nm ratio of each sample was determined. For cDNA synthesis, 1 µg of RNA was amplified using iScript cDNA Reverse Transcriptase Kit (Bio-Rad Laboratories, Hercules, CA). The reactions were carried out in a thermocycler (Bio-Rad Laboratories, Hercules, CA) as follows: 25ºC for 5 min, 46º for 20 min and 95ºC for 1 min for 40 cycles. The samples were stored at −20ºC until further processing.
Stool collection and microbial DNA extraction
Stool samples from the animals were collected at PND60, and DNA was extracted using RNeasy Power Microbiome kit (QIAGEN GmbH, Hilden, Germany) with minor adaptations. Briefly, an additional heating step of 95 °C for 10 min after step 4 was added because this step was previously shown to increase the DNA yield29. Genomic DNA was eluted in 100 µL of RNase-free H2O and quantified using Nanodrop. For downstream applications, samples were diluted to 50 ng/µL.
Real-time qPCR analysis
Real-time quantitative polymerase chain reaction (RT-qPCR) of microbial DNA, and brain and intestinal cDNA was performed using primers listed in the Additional File, Table 1. RT-qPCR was performed in mixture containing SsoAdvanced Universal SYBR Green Supermix (Bio-rad Laboratories, Hercules, CA), 500 nM primers and 20 ng of cDNA or 100 ng of bacterial DNA. The amount of cDNA input for qPCR (20 ng) was calculated based on the initial RNA quantification, following the manufacturer’s recommendations for the reverse transcription kit. All reactions were multiplexed with the housekeeping genes B2M, YWHAZ and HRPT (for the brain and intestine) and 16S (for intestinal bacteria). Reactions were carried out with a CFX PCR System (Bio-Rad Laboratories, Hercules, CA). The expression of each gene was compared between groups using the 2-ΔΔCT method30. For all the qPCR reactions, every sample was amplified in duplicate. To ensure specific amplification, qPCR mixtures without DNA were included as negative controls. Additionally, to validate the specificity and efficiency of the amplification of the primers and probe, qPCR amplification was previously performed via a tenfold dilution series from template DNA, and an efficiency ranging from 90 to 110% was achieved. The choice of housekeeping genes was first based on primer efficiency comparisons between NF1 and WT samples, followed by evaluation of gene stability using RefFinder31.
Determination of the estrous cycle

Cortical NPY system expression in male and femalemouse. () Relative mRNA expression ofand their receptors,andin prefrontal cortex (PFC) of WT and mutant males and females. While no alterations were observed inmales, mutant females exhibited a significant decrease in NPY, Y1, and Y5 receptor levels. Graphs depict individual values, mean, and standard error (n = 9 – 19 per group). One-way ANOVA followed by Tukey’s post-hoc test was used for multiple comparisons. *p < 0.05, **p < 0.01. (–) mRNA expression of () NPY, () Y1, () Y2, and () Y5 across the estrous cycle infemales. No significant differences were observed. Graphs depict mean, and standard error (n = 6 – 3 per group). One-way ANOVA followed by Tukey’s post-hoc test was used for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. Nf1 NPY Y1 Y2 Y5 Nf1 Nf1 +- / + /- + /- A B E B C D E
Statistical analysis
Data analysis was performed in GraphPad Prism version 9 (GraphPad Software, San Diego, CA, USA). The outliers were identified and excluded after ROUT analysis (Q = 5%), which was applied conservatively to minimize the influence of extreme values on group means. Normality tests were performed via the Shapiro–Wilk test. The data are expressed as the mean ± SEM. One-way ANOVA followed by Tukey’s post-hoc test was used for multiple comparisons. The correlations were performed using Spearman’s analysis of absolute values of ΔCq. The correlation between each indicator was compared, and the correlation heat map was drawn using ChiPlot (https://www.chiplot.online/) (accessed on 12 March 2025). Since this work was intended to be hypothesis-generating, no formal multiple comparisons correction was applied across genes, brain regions, or estrous phases. The exact n distribution across the experimental groups, the values of mean ± SEM, p values and 95% confidence intervals of means are presented in additional files—Tables 2, 3, 4, 5.
Results
The levels of the brain NPY system are sex dependent in Nf1mice +/-
Several neuropsychiatric disorders, such as depression and schizophrenia34, have been linked to changes in NPY levels35,36. However, until now, possible alterations in the central NPY system under autistic conditions have remained unknown. Since early developmental dysfunction in the amygdala and hippocampus in individuals with ASD may cause a breakdown in brain connectivity normally recruited during complex cognitive tasks and trigger abnormal PFC development37, we focused our investigation on these three brain regions. The NPY system gene expression, namely the levels of NPY and its receptors Y1, Y2 and Y5, was analyzed. We found both region- and sex-dependent changes in the expression of these genes. Cortical levels of NPY, as well as Y1 and Y5, were lower in mutant females than in their WT littermates (Fig. 1A; NPY – Female WT: 1.242 ± 0.193, Female Nf1+/-: 0.645 ± 0.041, p = 0.0085; Y1 – Female WT: 0.999 ± 0.036, Female Nf1+/-: 0.616 ± 0.054, p = 0.0358; Y5 – Female WT: 1.372 ± 0.276, Female Nf1+/-: 0.626 ± 0.074, p = 0.0175). Interestingly, no sex differences in mRNA expression were detected between male and female Nf1+/- mice (Fig. 1A). Additionally, no changes were detected in the cortical male NPY or Y2 receptor levels (Fig. 1A). In vitro and in vivo studies suggest that NPY gene expression and its receptors are modulated by gonadotropic sex hormones38,39. Therefore, it is also important to consider the estrous cycle and fluctuating hormone levels when investigating the NPY system in females. However, no changes were detected in cortical NPY or its receptors between the follicular and luteal phases (Fig. 1B–E).
These results suggest a brain region- and sex-specific signature in the NPY system in a mouse model of ASD. We also found changes in the hippocampal and amygdalar NPY systems in females that were dependent on the estrous cycle; an interesting aspect requiring further validation.

Expression of the NPY system in the amygdala of male and femalemice. () Relative mRNA expression of NPY and its receptors (Y1, Y2, and Y5) in the amygdala of WT andmales and females. A significant upregulation of Y2 receptor mRNA was observed only infemales compared to both mutant males and WT littermates. Graphs depict individual values, mean, and standard error (n = 10 – 19 per group). *p < 0.05. (–) mRNA expression of (), (), (), and ()across the estrous cycle infemales. NPY, Y1, and Y5 showed upregulation during the luteal phase, while no changes were detected inexpression. Graphs depict mean, and standard error (n = 6—3). One-way ANOVA followed by Tukey’s post-hoc test was used for multiple comparisons. *p < 0.05, **p < 0.01, ***p < 0.001. Nf1 Nf1 Nf1 NPY Y1 Y2 Y5 Nf1 Y2 + /- + /- + /- + /- A B E B C D E

Hippocampal levels of the NPY system mRNA of male and femalemice. () Relative mRNA expression of NPY and its receptors (Y1, Y2, and Y5) in the hippocampus of WT andmales and females. Although no changes were observed in receptors,levels were increased in mutant males comparing withfemales and WT littermates. Graphs depict individual values, mean, and standard error (n = 10 – 19 per group)). One-way ANOVA followed by Tukey’s post-hoc test was used for multiple comparisons .*p < 0.05. (–) mRNA expression of (), (), (), and ()across the estrous cycle infemales. Y1, Y2 and Y5 estrous cycle-dependent expression in mutant females, characterized by a downregulation during follicular phase and an upregulation during luteal phase. Graphs depict mean, and standard error (n = 6 – 3 per group). One-way ANOVA followed by Tukey’s post-hoc test was used for multiple comparisons *p < 0.05, **p < 0.01, ***p < 0.001; ****p < 0.0001. Nf1 Nf1 NPY Nf1 NPY Y1 Y2 Y5 Nf1 + /- + /- + /- + /- A B E B C D E
Nf1mice exhibit alterations in the intestinal NPY system +/-
When we analyzed the expression of NPY, PYY, and their receptors Y2 and Y4 concerning the estrous cycle, we detected that only NPY mRNA expression showed cycle-dependent changes in Nf1+/- animals (NPY—Female Nf1+/- follicular phase: 16.66 ± 2.371, Female Nf1+/- luteal phase: 1.909 ± 0.475, p < 0.0001, Fig. 4B). Moreover, in the follicular phase, the mutated female had a significantly increase in NPY and Y2 levels comparing with their littermates WT, which was not observed in the luteal phase (NPY—Female WT follicular phase: 1.000 ± 0.421, p < 0.0001, Fig. 4B; Y2—Female WT follicular phase: 1.000 ± 0.724, p = 0.0433, Fig. 4D). Overall, our data indicate that, similar to that in the brain, the intestinal NPY system might be altered in an animal model of ASD in a sex-dependent manner.

mice exhibit sex-dependent changes in intestinal NPY system() Relative expression of intestinalandmRNA. Transgenic females overexpressed,andin the intestine. Mutant males only exhibited a decreased expression ofGraphs depict individual values, mean, and standard error (n = 9 – 20 per group)). One-way ANOVA followed by Tukey’s post-hoc test was used for multiple comparisons *p < 0.05; ***p < 0.001; ****p < 0.0001. (–) mRNA expression of (), (), (), and ()across the estrous cycle infemales. Intestinalandexpression was overexpressed only in the follicular phase of transgenic females. Graphs depict mean, and standard error (n = 6 – 3 per group)). One-way ANOVA followed by Tukey’s post-hoc test was used for multiple comparisons: *p < 0.05, ****p < 0.0001. Nf1 NPY, PYY, Y2 Y4 NPY, PYY Y2 Y4 Y2. NPY Y1 Y2 Y5 Nf1 NPY Y2 + /- + /- . A B E B C D E

females lose correlation between intestine and central NPY system. (,) Heatmap illustrating differential correlation data between intestine-brain in both () males and () females of control and transgenic mice. Correlation heatmap matrix were performed using Spearman’s analysis of absolute values of ΔCq. Significance levels are as follows: * p < 0.05, ** p < 0.01, *** p < 0.001. Nf1 + /- A B A B
Intestinal dysbiosis in female Nf1mice is associated with the intestinal NPY system +/-
To understand whether alterations in the Lactobacillus genus and species are associated with intestinal NPY system, an exploratory correlation analysis was performed (Fig. 6B,C). No correlations were found in both Nf1+/- and WT males (Fig. 6B). Contrary, in WT females, Lactobacillus abundance, especially L. rumni, was negatively correlated with intestinal NPY (Spearman r = -0.761, p < 0.0001), PYY (Spearman r = -0.641, p = 0.004), Y2 (Spearman r = -0.589, p = 0.006) and Y4 (Spearman r = -0.620, p = 0.010), Fig. 6C. Mutated females lost L.rumni-intestine NPYergic correlations, though negative correlations were observed between intestinal Y2 and Lactobacillus (Spearman r = -0.670, p = 0.011) and L.reuteri (Spearman r = −0.644, p = 0.015; Fig. 6C). To summarize, Nf1+/- animals showed alterations in Lactobacillus genus, some of which were associated with intestinal NPYergic system in females.

Dysbiosis in femalemice is strongly correlated with intestinal NPY system. () Characterization of the relative amount of genus Lactobacillus and species in the gut stool. Transgenic males displayed a reduction in the relative content of Lactobacillus. No alterations were observed in the females’ group. L reuteri levels were only reduced in the stool offemales. Concerning, no changes were detected among the groups. (,) Heatmap illustrating differential correlation data between intestine-gut microbiota in both () males and () females of control and transgenic mice. Correlation heatmap matrix were performed using Spearman’s analysis of absolute values of ΔCq. Significance levels are as follows: * p < 0.05, ** p < 0.01, *** p < 0.001. Nf1 Nf1 L. rumni + /- + /- A B C B C
Transgenic females are more susceptible to molecular changes in NPY gut-brain communication and the microbiota

Transgenic females exhibit a different molecular pattern of NPY along the microbiota-gut-brain-system. Transgenic females display a distinct populational cluster in PCA analysis. Populational clusters were obtained for wildtypes and transgenic from both sexes based on NPY-gut-brain expression and microbiota abundance. Percentage values in parentheses next to dimension 1 (Dim1) and dimension 2 (Dim2) represent the percentage of variance explained by each component.
Discussion
Our study provides the first evidence that the NPY system is altered in the gut-brain axis of a mouse model of ASD. These changes were mainly observed in female Nf1+/- mice and some were dependent on the estrous cycle. Interestingly, in females, we also found significant correlations between the intestinal and central NPYergic systems, as well as with Lactobacillus levels. These findings led us to hypothesize that the NPY system may play a crucial role in maintaining gut homeostasis.
NPY has been identified as a possible neurochemical mediator for the interaction of the gut-microbiota with brain function22. It was reported that the brain NPY system is severely disturbed by antibiotic-induced gut dysbiosis, namely in the hippocampus, amygdala and hypothalamus of adult male C57BL/6N mice46. More recently, another study using a model of postmenopausal osteoporosis showed NPY and Y1 modulated the microbial diversity and changed the community composition of the gut microbiome in ovariectomized female rats42. However, studies associating the NPYergic system with the changes observed in the gut-brain axis in individuals with autism are still lacking. Moreover, given the well-documented sexual dimorphisms in this system47, investigating how NPYergic alterations differ between males and females is crucial.
Our data suggests sex-dependent changes in the brain NPYergic system in Nf1+/- animals. While the main alterations in the NPY system were observed in the cortex and amygdala of transgenic females, changes in the hippocampus were exclusive to the Nf1+/- males. These findings support the hypothesis that male Nf1+/- mice are more prone to develop cognitive impairments, as reported by our group9. Under physiological conditions, central NPY plays a crucial role in modulating neuroplasticity, neurotransmission, and memory48 by regulating synaptic plasticity and cognitive functions49. Accordingly, under pathological conditions, treatment with NPY system modulators has been shown to reverse cognitive impairment42,50,51. Our previous study demonstrated that Nf1+/− females exhibited more severe anxiety-related traits9, which may be influenced by alterations in the cortical and amygdalar NPYergic system. The observed reduction in cortical NPY levels and increased Y2 receptor expression in the amygdala align with evidence suggesting that these molecular changes are associated with an enhanced anxiogenic phenotype23,24,26,52,53. Notably, reduced NPY levels have been consistently reported in both preclinical and clinical studies of depression, chronic stress, and post-traumatic stress disorder54–56. Furthermore, postmortem studies have revealed a significant decrease in NPY mRNA, along with an upregulation in Y2 mRNA in the hippocampus and PFC regions of individuals with depression and suicide behaviors57. Recent findings by Carbona et al. highlight important sex-dependent differences in NPY levels in the PFC of young juvenile rats, which are linked to anxiety-related behavior58. Although few studies have directly examined the causal relationship between Y2 in the amygdala and anxiogenesis, evidence suggests that activation of Y2 receptors, which are predominantly expressed on presynaptic terminals in the basolateral amygdala, can exacerbate anxiety behavior23. Based on these findings, we propose that dysfunction in the brain NPY system represents an adaptive functional response to counterbalance the behavioral impairments observed in Nf1+/- animals in a sex-dependent manner9.
Previous studies have suggested that the estrous cycle influences the expression of anxiety- and autism-like behaviors in rodents59,60. Moreover, other authors reported that fluctuations in circulating levels of estrogen and progesterone, depending by estrous cycle, are paralleled by changes in the expression of central NPY system61,62. Our findings align with this evidence. In our mouse model of ASD, we observed that the NPY system in the amygdala and hippocampus—two regions that work together to regulate the hypothalamic–pituitary–adrenal (HPA) axis—is influenced by the estrous cycle63. Notably, the most significant alterations in the amygdala occurred during the luteal phase, which coincided with the lowest levels of gonadal hormones. We hypothesize that the increase in NPY system levels during the luteal phase may be linked to the modulation of anxiety-related behavior. This is supported by findings from Lebron-Milad & Milad, who reported that females in the luteal phase exhibit greater anxiety-like behavior than do those in the follicular phase or males64. Interestingly, compared with those in WT females, NPY receptor levels in the hippocampus are downregulated during the follicular phase and upregulated during the luteal phase. The NPY system is a well-established neuromodulator widely distributed in the hippocampus65 playing a crucial role in cognitive processing66. Our findings are in agreement with recent advancements in multiphoton imaging techniques, which highlight the estrous cycle as a driver of large-scale structural and functional plasticity in the hippocampal circuits essential for learning and memory67.
The NPY system may act as a neurochemical mediator in the gut-brain axis22, and our findings support this hypothesis. In addition to alterations in the central NPY system, we also observed changes in the intestinal NPY system, which were once again sex-dependent. Our study provides evidence that females Nf1+/- mice are particularly susceptible to transcriptomic changes in intestinal NPY, PYY, and their receptor Y4. Interestingly, the expression patterns of intestinal Y2 differed between males and females. While Nf1+/- males showed a significant reduction in Y2 expression, mutant females showed an increase. Notably, these alterations were not influenced by the estrous cycle. Previously, our group have demonstrated that female Nf1+/- mice show surprisingly better spatial memory performance, in contrast to the severe cognitive impairments observed in male Nf1+/- mice9. Accordingly, gastrointestinal issues have been correlated with poorer cognitive performance in ASD cases68. Furthermore, the higher prevalence of ASD in boys may be linked to distinct changes in the intestinal microbiome compared to affected girls69. On the other hand, given that both autistic female70–72 and Nf1+/- females9 are more prone to developing, our results provide evidence that NPY signaling could be a promising pathway involved in intestinal-cognitive dysfunction in individuals with ASD. Consistent with this hypothesis, we found that some correlations between the cortical and hippocampal NPY systems and the intestinal NPY system were lost in mutant females, while new correlations were observed in the amygdala. Overall, we suggest that sex-biased dysfunction of the NPYergic system could provide an important framework for understanding gut-brain abnormalities in individuals with ASD.
Impaired gastrointestinal function is accompanied by an imbalance in the composition of the microbiota73. Biological sex is also thought to play a prominent role in the sexual dimorphism of gut microbiota18,44,74. Here, we have also reported a sex-dependent dysbiosis in the Lactobacillus genus and L. reuteri in Nf1+/- animal model. We found that transgenic females exhibited decreased levels of L. reuteri, whereas males presented decreased levels of the Lactobacillus genus. Accordingly, Tabouy et al. found that dysregulation of Lactobacillus and L.reuteri in the gut of both males and females of Shank3-/- mice is associated with social impairments and stereotypic-like behaviors17. Furthermore, another study found that administration of a specific strain L. reuteri ameliorated social deficits in several ASD mouse models44. While this targeted approach allowed us to investigate a genetically relevant and functionally important bacterial genus, we acknowledge that PCR-based profiling provides a limited view of the gut microbiome. In addition to confirming these changes in the Lactobacillus genus, we found an association between dysbiosis and the intestinal NPYergic system. The negative correlations found in WT females between the intestinal NPYergic system and L. rumni were lost in Nf1+/- females, which in turn, developed a new significant correlation between L. reuteri and intestinal Y2. No changes were detected in males. This finding leads us to postulate that an increase in intestinal Y2 could be a strategy to minimize to negative effect of dysbiosis, at least in ASD females. Previous studies hypothesized that restoring levels of L. reuteri resulted in higher levels of oxytocin, a hormone associated with social behavior17,18,44. With our results, we provide new evidence that L. reuteri could model other peptide systems at the level of the gut-brain axis, namely the NPY system. In fact, recently, new finding exploring the influence of gut microbiota on NPY expression in the colon and the concomitant alteration in the NPY of hippocampus, pointed out a microbiome-based therapy to precisely adjust the expression and function of NPY75. Therefore, understanding the intricate interplay between gut microbiota and NPY holds great promise for improving the holistic care of individuals with neurodevelopmental disorders.
Limitations
Despite the significant findings of this study, several important considerations remain. First, to generalize these conclusions, it is essential to examine additional ASD mutant mouse models, particularly focusing on NPY expression as explored in this study. Different ASD mouse models may exhibit varying patterns of NPY expression in the colon and key brain regions involved in social behavior, such as the amygdala, hippocampus, and prefrontal cortex, with potential differences based on biological sex. Second, while PCR is a powerful tool for quantifying the relative abundance of gut microbial species, its effectiveness is limited by the small number of genera and species analyzed. To achieve a more comprehensive understanding of gut microbiota composition, future research should integrate complementary techniques that offer greater sensitivity and resolution. Further, our study reports transcriptional changes; it is important to note that mRNA alterations do not always directly translate into protein-level changes due to post-transcriptional regulation and protein stability. Third, given the well-established influence of the menstrual cycle on female physiology, increasing the sample size could provide clearer insights into the role of menstrual phases in ASD pathophysiology through an NPY-dependent mechanism. Lastly, the relationship between alterations in the gut-brain NPY system and microbiota dysbiosis remains unclear. To address this gap, targeted microbiota-based interventions, such as probiotic supplementation or fecal microbiota transplants, should be explored as potential strategies for precisely modulating the gut microbiome and elucidating its impact on the gut-brain axis. Finally, the correlation analyses were conducted with an exploratory, hypothesis-generating aim, which constitutes an important limitation worth highlighting. Consequently, the observed associations should be interpreted with caution, as they may reflect spurious or non-causal relationships.
Conclusion
Our work suggests for the first time that the NPYergic receptor system may represent an underlying molecular contributor to the association between gastrointestinal dysfunction and the brain pathophysiology of ASD. The interaction between the brain and gut was influenced by both sex and specific regions. Female ASD mice appear to be more vulnerable to NPYergic changes in both the gut and brain, and some changes seem to be modulated by gonadal hormones during the estrous cycle. The intestinal Y2 receptor has emerged as a promising biomarker for understanding ASD-related gut-brain dysfunction. These alterations in the NPY system were also correlated with microbiome dysbiosis, a key characteristic observed in individuals with autism. Collectively, these findings are important for advancing our understanding of atypical development in patients with neuropsychiatric disorders such as ASD. These findings open new avenues for exploring sex-dependent interactions between the brain, gut, and microbiome, with the NPYergic system identified as a critical player in this relationship.
Supplementary Information
Supplementary Information.